Cetoquagene parvec clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses cetoquagene parvec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2006 (1)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2015 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
MeiraGTx, LLC (1) · MeiraGTx UK II Ltd (1) · National Institute of Dental and Craniofacial Research (NIDCR) (1)
Studies
Open first, then newest update. How each study uses cetoquagene parvec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary HypofunctionCompletedPhase 1MeiraGTx, LLCNCT02446249Written as AAV2hAQP1
- A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and XerostomiaCompletedPhase 1MeiraGTx UK II LtdNCT04043104Written as AAV2hAQP1: 1 x 10^11 vg/gland (single gland)
- Effect of AdhAQP1 on Salivary Flow in Patients Treated With Radiation for Head and Neck CancerCompletedPhase 1National Institute of Dental and Craniofacial Research (NIDCR)NCT00372320Written as AdhAQP1
Codes
What other systems call cetoquagene parvec · ClinicalTrials.gg INT016986
- UNII (FDA) JXQ6DJ9TW6CETOQUAGENE PARVECOne source FDA
- NCI Thesaurus C68932Cetoquagene ParvecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | JXQ6DJ9TW6 | CETOQUAGENE PARVEC | One source FDA |
| NCI Thesaurus | C68932 | Cetoquagene Parvec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.